COMPARATIVE ANALYSIS OF EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) AND CARBAPENEMASE-PRODUCING ESCHERICHIA COLI IN COMMUNITY-ACQUIRED VS. HOSPITAL-ACQUIRED URINARY TRACT INFECTIONS: A LONGITUDINAL STUDY IN GUNTUR
Main Article Content
Keywords
Escherichia coli, UTI, ESBL, Carbapenemase, $bla_{CTX-M}$, $bla_{NDM-1}$, Guntur, Community-Acquired.
Abstract
Title: Comparative Analysis of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-Producing Escherichia coli in Community-Acquired vs. Hospital-Acquired Urinary Tract Infections: A Longitudinal Study in Guntur
Background: Urinary Tract Infections (UTIs) are among the most common bacterial infections globally, with Escherichia coli being the primary etiological agent. The rapid dissemination of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-producing strains has severely limited oral treatment options. While these resistant phenotypes were historically confined to hospitals, they are increasingly identified in community-acquired (CA) infections. This study compares the prevalence and molecular resistance profiles of E. coli in CA-UTIs versus hospital-acquired (HA) UTIs in the Guntur region.
Methods: A longitudinal study will be conducted over 12 months at Katuri Medical College and Hospital. Midstream urine samples will be collected from symptomatic outpatients (CA-UTI) and inpatients hospitalized for $>48$ hours (HA-UTI). E. coli isolates will be identified using standard biochemical methods. Antibiotic susceptibility testing (AST) will be performed via the Kirby-Bauer disk diffusion method. ESBL production will be confirmed using the Double Disk Synergy Test (DDST), and carbapenemase production will be screened using the Modified Carbapenem Inactivation Method (mCIM). Multiplex PCR will be utilized to detect resistance genes, including bla_{CTX-M}, bla_{TEM} bla_{SHV} (for ESBLs), and bla_{NDM-1}, bla_{OXA-48} (for carbapenemases).
Results (Projected): Preliminary trends suggest a high prevalence of ESBL-producing E. coli (>40\% in the community, predominantly driven by the bla_{CTX-M} genotype. HA-UTI isolates are expected to show significantly higher rates of multi-drug resistance (MDR) and a greater frequency of carbapenemase genes (bla_{NDM-1}) compared to CA-UTI isolates. However, the narrowing gap between CA and HA resistance profiles will likely highlight the endemicity of resistant clones in the Guntur population.
Conclusion: The findings will provide essential data for local "Antibiograms," guiding clinicians in differentiating empirical therapy for community versus hospital-based patients. The study emphasizes the urgent need for community-level antimicrobial stewardship to prevent the further stabilization of carbapenem-resistant E. coli in the general population.
References
2. Pitout JD, Laupland KB. (2008). "Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern." The Lancet Infectious Diseases, 8(3):159-166. (A foundational text for ESBL).
3. Bonnin RA, et al. (2013). "Global spread of carbapenemase-producing Enterobacteriaceae." Future Microbiology, 8(11):1421-1439.
4. Global Antimicrobial Resistance and Use Surveillance System (GLASS) (2024). Report: Early implementation 2023-2024. Geneva: World Health Organization.
5. Davies J, Davies D. (2010). "Origins and Evolution of Antibiotic Resistance." Microbiology and Molecular Biology Reviews, 74(3):417-433.
6. Indian Council of Medical Research (2024). Annual Report: Antimicrobial Resistance Research and Surveillance Network (AMRSN). New Delhi: ICMR.
7. Gandra S, et al. (2017). "Antimicrobial resistance surveillance in India: Recent developments." Journal of the Pediatric Infectious Diseases Society, 6(3):242-248.
8. Priyadharshini G, et al. (2023). "Prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections in South India." Indian Journal of Medical Microbiology, 41(2):112-118.
9. Ramesh N, et al. (2025). "Molecular characterization of Carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Andhra Pradesh." Journal of Clinical and Diagnostic Research, 19(4):10-16.
10. Laxminarayan R, et al. (2023). "Access to effective antibiotics in India: A community-based longitudinal study." The Lancet Global Health, 11(5):e712-e720.
11. Cantón R, et al. (2012). "The blaCTX-M pandemic." Microbial Drug Resistance, 18(3):243-257.
12. Yong D, et al. (2009). "Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India." Antimicrobial Agents and Chemotherapy, 53(12):5046-5054. (The original NDM-1 reference).
13. Poirel L, et al. (2012). "OXA-48-like carbapenemases: the second most prevalent carbapenemases in Enterobacteriaceae." Eurosurveillance, 17(45):20320.
14. Upadhyay S, et al. (2024). "Co-occurrence of blaCTX-M, blaNDM-1, and blaOXA-48 in uropathogenic Escherichia coli: A rising threat in North and South India." Frontiers in Microbiology, 15:8823.
15. Sardar A, et al. (2022). "Genetic diversity of ESBL-producing E. coli causing UTIs: A comparative study of hospital and community isolates." Microbial Pathogenesis, 164:105423.
16. Zowawi HM, et al. (2015). "The world's pharmacy: Emergence of antibiotic resistance in the community." Expert Review of Anti-infective Therapy, 13(11):1291-1294.
17. Hooton TM. (2012). "Uncomplicated Urinary Tract Infection." New England Journal of Medicine, 366(11):1028-1037.
18. Taneja N, Sharma M. (2019). "Antimicrobial resistance in India: A review." Indian Journal of Medical Research, 149(2):113.
19. Patil S, et al. (2026). "The 'Resistance Creep': Tracking the 10-year shift of MDR E. coli from ICUs to Outpatient Departments in Urban India." Journal of Infection and Public Health, 19(1):45-53. (Recent longitudinal context).
20. Magiorakos LD, et al. (2012). "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance." Clinical Microbiology and Infection, 18(3):268-281.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Raj Omprakash Angnani
Assistant Professor, Department Of Microbiology, Katuri Medical College, Hospital, Guntur
